Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, proof-of-concept, Phase 2 trial evaluating safety and efficacy of Otlertuzumab in combination with bendamustine in patients with relapsed or refractory peripheral T-cell lymphomas (PTCL)

Next Previous
X
Search
Trial Profile

An open-label, proof-of-concept, Phase 2 trial evaluating safety and efficacy of Otlertuzumab in combination with bendamustine in patients with relapsed or refractory peripheral T-cell lymphomas (PTCL)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bendamustine (Primary) ; Otlertuzumab (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Proof of concept; Therapeutic Use

    • Most Recent Events

    • 14 Nov 2018 According to an Aptevo Therapeutics financial report, results were presented.
    • 13 Mar 2018 According to an Aptevo Therapeutics media release, the company anticipates to report preliminary data in Q4 2018.
    • 08 Jan 2018 Status changed from planning to recruiting, according to an Aptevo Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top